RNAZ - Transcode Therapeutics, Inc.

0.388
-0.057   -14.691%

Share volume: 1,967,221
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$0.44
-0.06
-0.13%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
17%
Profitability 0%
Dept financing 44%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-15.32%
1 Month
-71.68%
3 Months
-88.17%
6 Months
-28.27%
1 Year
-39.39%
2 Year
-94.89%
Key data
Stock price
$0.39
P/E Ratio 
0.00
DAY RANGE
$0.37 - $0.45
EPS 
-$34.60
52 WEEK RANGE
$0.22 - $16.73
52 WEEK CHANGE
-$39.42
MARKET CAP 
9.859 M
YIELD 
N/A
SHARES OUTSTANDING 
17.266 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
4.07
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,673,458
AVERAGE 30 VOLUME 
$15,595,799
Company detail
CEO: Robert M. Dudley
Region: US
Website: transcodetherapeutics.com
Employees: 9
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

TransCode Therapeutics, Inc. engages in the development and commercialization of drugs and diagnostics. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Recent news
loading